Table 4– Characteristics of chronic obstructive pulmonary disease (COPD) subjects who were evaluated for systemic levels of soluble receptor for advanced glycation end-products

	Neutrophilic COPD	COPD	p-value
Subjects n	18	16
Age yrs	69 (57.58–79.61)	70 (59.69–82.65)	0.8
Males/females n	7/11	9/7	0.5
Atopy n (%)	6 (33)	4 (25)	0.3
Pre-bronchodilator FEV₁ % pred	45.1±14.6	51.4±16.5	0.2
Smoking status current/ex/never n	0/12/6	1/10/5	0.8
Smoking history pack-yrs	30.3 (0–71.6)	37.7 (0.2–102.5)	0.8
ICS use %	83.33	93.75	0.8
Total daily ICS dose μg beclamethasone equivalent^#	1000 (500–2000)	1000 (500–1750)	0.6

Data are presented as median (interquartile range) or mean±sd, unless otherwise stated. FEV₁: forced expiratory volume in 1 s; % pred: % predicted; ICS: inhaled corticosteroids; ns: nonsignificant. ^#: total daily ICS dose (beclamethasone equivalents), based on the assumption that 1 μg beclamethasone=1 μg budesonide=0.5 μg fluticasone.